| Year |
Citation |
Score |
| 2023 |
Murphy T, Mason JM, Leber B, Bray MR, Chan SM, Gupta V, Khalaf D, Maze D, McNamara CJ, Schimmer AD, Schuh AC, Sibai H, Trus M, Valiquette D, Martin K, et al. Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia. PMID 38114624 DOI: 10.1038/s41375-023-02110-9 |
0.338 |
|
| 2023 |
Murphy T, Zou J, Arruda A, Wang TT, Zhao Z, Zheng Y, Gupta V, Maze D, McNamara C, Minden MD, Schimmer A, Sibai H, Yee K, Capo-Chichi JM, Stockley T, ... ... Chan SM, et al. Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia. Haematologica. PMID 37345484 DOI: 10.3324/haematol.2023.283510 |
0.311 |
|
| 2023 |
Nampoothiri RV, Tang K, Schuh A, Lam W, Maze D, Michelis FV, Chan S, Gupta V, Kim D, Kumar R, Lipton JH, Mattsson J, Minden M, Schimmer A, Sibai H, et al. Mutational Profile, Outcomes, and Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and Inconclusive Cytogenetic Analysis. European Journal of Haematology. PMID 36732677 DOI: 10.1111/ejh.13940 |
0.341 |
|
| 2022 |
Liu ACH, Cathelin S, Yang Y, Dai DL, Manikoth Ayyathan D, Hosseini M, Minden MD, Tierens A, Chan SM. Targeting STAT5 signaling overcomes resistance to IDH inhibitors in acute myeloid leukemia through suppression of stemness. Cancer Research. PMID 36150062 DOI: 10.1158/0008-5472.CAN-22-1293 |
0.448 |
|
| 2022 |
Vanner RJ, Dobson SM, Gan OI, McLeod J, Schoof EM, Grandal I, Wintersinger JA, Garcia-Prat L, Hosseini M, Xie SZ, Jin L, Mbong N, Voisin V, Chan-Seng-Yue M, Kennedy JA, ... ... Chan SM, et al. Multiomic Profiling of Central Nervous System Leukemia Identifies mRNA Translation as a Therapeutic Target. Blood Cancer Discovery. 3: 16-31. PMID 35019858 DOI: 10.1158/2643-3230.BCD-20-0216 |
0.32 |
|
| 2021 |
Cathelin S, Sharon D, Subedi A, Cojocari D, Phillips DC, Leverson JD, MacBeth KJ, Nicolay B, Narayanaswamy R, Ronseaux S, Liu G, Chan SM. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia. Leukemia. PMID 34743189 DOI: 10.1038/s41375-021-01468-y |
0.393 |
|
| 2021 |
Chow S, Tang K, Al-Abri M, Hall V, Tremblay-Lemay R, Rashedi I, Tsui H, Chan SM. RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia. Leukemia Research. 111: 106735. PMID 34735933 DOI: 10.1016/j.leukres.2021.106735 |
0.323 |
|
| 2021 |
Subedi A, Liu Q, Ayyathan DM, Sharon D, Cathelin S, Hosseini M, Xu C, Voisin V, Bader GD, D'Alessandro A, Lechman ER, Dick JE, Minden MD, Wang JCY, Chan SM. Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis. Cell Stem Cell. PMID 34293334 DOI: 10.1016/j.stem.2021.06.004 |
0.32 |
|
| 2021 |
Daher-Reyes G, Kim T, Novitzky-Basso I, Kim KH, Smith A, Stockley T, Capochichi JM, Al-Shaibani Z, Pasic I, Law A, Lam W, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, ... ... Chan S, et al. Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation. PMID 33767401 DOI: 10.1038/s41409-021-01255-4 |
0.364 |
|
| 2020 |
Abelson S, Zeng AGX, Nofech-Mozes I, Wang TT, Ng SWK, Minden MD, Pugh TJ, Awadalla P, Shlush LI, Murphy T, Chan SM, Dick JE, Bratman SV. Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing. Science Advances. 6. PMID 33298453 DOI: 10.1126/sciadv.abe3722 |
0.306 |
|
| 2020 |
Mirali S, Botham A, Voisin V, Xu C, St-Germain J, Sharon D, Hoff FW, Qiu Y, Hurren R, Gronda M, Jitkova Y, Nachmias B, MacLean N, Wang X, Arruda A, ... ... Chan SM, et al. The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. Science Translational Medicine. 12. PMID 32269163 DOI: 10.1126/Scitranslmed.Aaz8264 |
0.321 |
|
| 2020 |
Puckrin R, Atenafu EG, Claudio JO, Chan S, Gupta V, Maze D, McNamara C, Murphy T, Shuh AC, Yee K, Sibai H, Minden MD, Wei C, Stockley T, Kamel-Reid S, et al. Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica. PMID 31896684 DOI: 10.3324/Haematol.2019.235721 |
0.337 |
|
| 2020 |
Subedi A, Liu Q, Sharon D, Cathelin S, Bader GD, Xu C, Voisin V, D'Alessandro A, Lechman ER, Dick JE, Minden MD, Wang JC, Chan SM. Nicotinamide Phosphoribosyltransferase Inhibitors Induce Apoptosis of AML Stem Cells through Dysregulation of Lipid Metabolism Blood. 136: 25-26. DOI: 10.1182/BLOOD-2020-142404 |
0.302 |
|
| 2020 |
Liu Q, Subedi A, Yao S, Xu C, Voisin V, Bader GD, Chan SM, Wang JC. A Stemness-Based Screen Identifies PLK1 Inhibitors for Targeting Leukemia Stem Cells in AML Blood. 136: 34-35. DOI: 10.1182/blood-2020-141740 |
0.34 |
|
| 2019 |
Murphy T, Zou J, Daher-Reyes GS, Arruda A, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KWL, Korulla M, Stockley T, Kamel-Reid S, Maze D, Tierens A, ... ... Chan SM, et al. Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML. Blood Advances. 3: 2307-2311. PMID 31371380 DOI: 10.1182/Bloodadvances.2019000306 |
0.337 |
|
| 2019 |
Seneviratne AK, Xu M, Aristizabal Henao JJ, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, ... ... Chan S, et al. The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids. Cell Stem Cell. 24: 1007. PMID 31173706 DOI: 10.1016/J.Stem.2019.04.020 |
0.304 |
|
| 2019 |
Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. American Journal of Hematology. PMID 30945331 DOI: 10.1002/ajh.25484 |
0.541 |
|
| 2019 |
Daher-Reyes GS, Kim T, Kim KH, Ahn J, Stockley TL, Capo-Chichi JM, Al-Shaibani Z, Law A, Lam W, Michelis FV, Viswabandya A, Lipton JH, Kumar R, Mattsson J, Schimmer AD, ... ... Chan SM, et al. Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Blood. 134: 3317-3317. DOI: 10.1182/Blood-2019-125780 |
0.33 |
|
| 2019 |
Murphy T, Zou J, Wang TT, Zheng Y, Zhao Z, Shapiro RM, Gupta V, Maze D, McNamara CJ, Minden MD, Schimmer AD, Schuh AC, Sibai H, Yee KW, Stockley TL, ... ... Chan SM, et al. High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia Blood. 134: 1424-1424. DOI: 10.1182/Blood-2019-122890 |
0.306 |
|
| 2019 |
Mirali S, Aaron B, Voisin V, Xu C, St-Germain J, Sharon D, Hoff FW, Qiu Y, Hurren R, Gronda M, Jitkova Y, Xu GW, Nachmias B, MacLean N, Wang X, ... ... Chan SM, et al. The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability Blood. 134: 729-729. DOI: 10.1182/Blood-2019-122784 |
0.364 |
|
| 2019 |
Dinardo C, Takahashi K, Kadia T, Loghavi S, Naqvi K, Bose P, Daver N, Tippett G, Borthakur G, Cortes J, Chan S, Quek L, Vyas P, Kantarjian H, Konopleva M. PF291 A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES Hemasphere. 3: 97. DOI: 10.1097/01.HS9.0000559376.17429.23 |
0.328 |
|
| 2019 |
Andrews C, Atenafu EG, Murphy T, Al-Shaibani Z, Chan SM, Gupta V, Kim DDH, Kumar R, Lam W, Lipton JH, Mattsson J, Maze D, Michelis F, McNamara CJ, Schimmer AD, et al. Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia Blood. 134: 5725-5725. DOI: 10.1016/J.Bbmt.2019.12.642 |
0.303 |
|
| 2018 |
Alduaij W, McNamara CJ, Schuh A, Arruda A, Sukhai M, Kanwar N, Thomas M, Spiegel J, Kennedy JA, Stockley T, Tsui H, Devlin R, Sibai H, Maze D, Schimmer A, ... ... Chan S, et al. Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience. Hemasphere. 2: e44. PMID 31723772 DOI: 10.1097/HS9.0000000000000044 |
0.31 |
|
| 2018 |
McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, Ho J, Siddiq N, Devlin R, Tsui H, Su J, Stockley T, Sukhai M, Kanwar N, Chan S, et al. The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. Blood Advances. 2: 2658-2671. PMID 30327374 DOI: 10.1182/Bloodadvances.2018021469 |
0.467 |
|
| 2018 |
Cathelin S, Sharon D, Subedi A, Cojocari D, Phillips DC, Leverson JD, MacBeth K, Nicolay B, Narayanaswamy R, Ronseaux S, Liu G, Chan SM. Combination of Enasidenib and Venetoclax Shows Superior Anti-Leukemic Activity Against IDH2 Mutated AML in Patient-Derived Xenograft Models Blood. 132: 562-562. DOI: 10.1182/BLOOD-2018-99-119688 |
0.386 |
|
| 2018 |
Daher-Reyes GS, McNamara CJ, Maganti M, Stockley TL, Capo-Chichi JM, Alkharras RA, Arruda A, Claudio J, Chan SM, Schimmer AD, Minden MD, Sibai H, Yee KW, Gupta V, Kamel-Reid S, et al. Impact of Genetic Profile on Clinical Outcomes in Adults ≥60 with AML: The Princess Margaret Cancer Centre Experience Blood. 132: 2666-2666. DOI: 10.1182/Blood-2018-99-118938 |
0.375 |
|
| 2018 |
Liu Q, Subedi A, Xu C, Voisin V, Bader GD, Chan SM, Wang JC. Identification of Compounds That Target Acute Myeloid Leukemia Stem Cells Using a Scalable Next-Generation Screening Platform Blood. 132: 259-259. DOI: 10.1182/blood-2018-99-115323 |
0.359 |
|
| 2018 |
Singh RP, Jeyaraju DV, Voisin V, Xu C, Barghout SH, Khan DH, Hurren R, Gronda M, Wang X, Jitkova Y, Sharon D, Liyanage SU, Soriano J, Lechman, ER, ... ... Chan SM, et al. Targeting the Mitochondrial Metallochaperone Cox17 Reduces DNA Methylation and Promotes AML Differentiation through a Copper Dependent Mechanism Blood. 132: 1339-1339. DOI: 10.1182/Blood-2018-99-111015 |
0.37 |
|
| 2018 |
Murphy T, Zou J, Daher-Reyes GS, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KW, Stockley TL, Kamel-Reid S, Maze D, Bratman S, Schuh A, Chan SM. Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations Blood. 132: 992-992. DOI: 10.1016/J.Clml.2019.07.113 |
0.475 |
|
| 2017 |
McKeown MR, Corces MR, Eaton ML, Fiore C, Lee E, Lopez JT, Chen MW, Smith D, Chan SM, Koenig JL, Austgen K, Guenther MG, Orlando DA, Lovén J, Fritz CC, et al. Super-Enhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. Cancer Discovery. PMID 28729405 DOI: 10.1158/2159-8290.Cd-17-0399 |
0.6 |
|
| 2017 |
Farshchi Zarabi S, Chan S, Gupta V, Khalaf D, Lutynski A, Minden MD, Rostom A, Rydlewski A, Schuh AC, Sibai H, Yee KWL, Schimmer AD. Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived. Leukemia & Lymphoma. 1-4. PMID 28595467 DOI: 10.1080/10428194.2017.1323273 |
0.324 |
|
| 2017 |
Sinha S, Thomas D, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Hernandez D, Chan A, Rankin EB, Bernards R, Majeti R, Dill DL. Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature Communications. 8: 15580. PMID 28561042 DOI: 10.1038/Ncomms15580 |
0.746 |
|
| 2017 |
Heath E, Chan SM, Minden MD, Murphy T, Shlush LI, Schimmer AD. Biological and clinical consequences of NPM1-mutations in AML. Leukemia. PMID 28111462 DOI: 10.1038/leu.2017.30 |
0.426 |
|
| 2017 |
Sinha S, Thomas D, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Bernards R, Majeti R, Dill DL. Abstract A27: Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer primary tumor data Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A27 |
0.754 |
|
| 2016 |
Matre P, Velez J, Jacamo R, Qi Y, Su X, Cai T, Chan SM, Lodi A, Sweeney SR, Ma H, Davis RE, Baran N, Haferlach T, Su X, Flores ER, et al. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget. PMID 27806325 DOI: 10.18632/Oncotarget.12944 |
0.394 |
|
| 2016 |
Huang M, Garcia JS, Thomas D, Zhu L, Nguyen LX, Chan SM, Majeti R, Medeiros BC, Mitchell BS. Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget. PMID 27732946 DOI: 10.18632/Oncotarget.12493 |
0.63 |
|
| 2016 |
Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. PMID 27721426 DOI: 10.1038/leu.2016.275 |
0.416 |
|
| 2016 |
Corces MR, Buenrostro JD, Wu B, Greenside PG, Chan SM, Koenig JL, Snyder MP, Pritchard JK, Kundaje A, Greenleaf WJ, Majeti R, Chang HY. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nature Genetics. PMID 27526324 DOI: 10.1038/Ng.3646 |
0.63 |
|
| 2016 |
Law AD, Sukhai MA, Thomas M, Arruda A, Ibrahimova N, Chan SM, Gupta V, Minden MD, Schimmer AD, Sibai H, Yee KW, Barber DL, Stockley TL, Kamel-Reid S, Schuh AC. Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations Blood. 128: 2886-2886. DOI: 10.1182/Blood.V128.22.2886.2886 |
0.416 |
|
| 2016 |
Thomas D, Sinha S, Chan SM, Wu M, Torabi D, Peltz G, Gao Y, Dill DL, Majeti R. Isocitrate Dehydrogenase 1 Mutant Cancers Are Metabolically Vulnerable to Inhibition of Acetyl CoA Carboxylase Via a 2-Hydroxyglutarate Independent Mechanism Blood. 128: 1054-1054. DOI: 10.1182/Blood.V128.22.1054.1054 |
0.624 |
|
| 2015 |
Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R, Corces MR, Flynn RA, Buenrostro JD, Chan SM, Thomas D, Koenig JL, Hong WJ, Chang HY, Majeti R. Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell Stem Cell. PMID 26607380 DOI: 10.1182/Blood.V126.23.841.841 |
0.718 |
|
| 2015 |
Reinisch A, Chan SM, Thomas D, Majeti R. Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Seminars in Hematology. 52: 150-64. PMID 26111462 DOI: 10.1053/J.Seminhematol.2015.03.008 |
0.723 |
|
| 2015 |
Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA, Majeti R. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine. 21: 178-84. PMID 25599133 DOI: 10.1038/Nm.3788 |
0.696 |
|
| 2015 |
Sinha S, Thomas D, Yu L, Gentles AJ, Jung N, Corces-Zimmerman MR, Chan SM, Reinisch A, Feinberg AP, Dill DL, Majeti R. Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood. 125: 316-26. PMID 25398938 DOI: 10.1182/Blood-2014-03-566018 |
0.738 |
|
| 2015 |
Sinha S, Thomas D, Chan SM, Gao Y, Jansen R, Majeti R, Dill DL. Boolean Implication Mining for Synthetic Lethal Interactions in AML Identifies Acetyl-CoA Carboxylase As a Synthetic Lethal Partner of the IDH1 mutation Blood. 126: 1404-1404. DOI: 10.1182/Blood.V126.23.1404.1404 |
0.611 |
|
| 2015 |
Sinha S, Thomas D, Gao Y, Chan SM, Brunen D, Bernards R, Majeti R, Dill DL. Abstract LB-B07: MiSL: a method for mining synthetic lethal partners of somatic mutations identifies acetyl-CoA carboxylase as a synthetic lethal interactor of the IDH1 mutation in Leukemia Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-B07 |
0.709 |
|
| 2014 |
Nguyen le XT, Chan SM, Ngo TD, Raval A, Kim KK, Majeti R, Mitchell BS. Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells. Blood. 124: 579-89. PMID 24850755 DOI: 10.1182/Blood-2013-12-544726 |
0.537 |
|
| 2014 |
Chan SM, Thomas D, Medeiros BC, Majeti R. Isocitrate Dehydrogenase Mutations Induce BCL-2 Dependence in Acute Myeloid Leukemia through Inhibition of Cytochrome C Oxidase Function Blood. 124: 615-615. DOI: 10.1182/Blood.V124.21.615.615 |
0.699 |
|
| 2014 |
Matre P, Shariati M, Velez J, Qi Y, Konoplev S, Su X, DiNardo CD, Daver N, Majeti R, Andreeff M, Chan SM, Konopleva M. Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia Blood. 124: 3763-3763. DOI: 10.1182/Blood.V124.21.3763.3763 |
0.416 |
|
| 2013 |
Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. International Journal of Hematology. 98: 648-57. PMID 23949914 DOI: 10.1007/S12185-013-1407-8 |
0.668 |
|
| 2013 |
Huang M, Thomas D, Li MX, Feng W, Chan SM, Majeti R, Mitchell BS. Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia. 27: 1970-80. PMID 23877794 DOI: 10.1038/Leu.2013.222 |
0.689 |
|
| Show low-probability matches. |